- Healing Properties
- November 13, 2018
Overwhelmed with thoughts of accidental deaths and a crippling fear of crowds, McKenzi Murdock, a 31-year-old biology major at OSU, found herself debilitated by her anxiety and unable to leave the house.
Murdock felt worn down, unmotivated and struggled to manage school and her life. In an effort to combat her fears and desperately searching for relief, Murdock took the advice of a family member and started using the herbal drug kratom three years ago.
“It changed my whole outlook on life,” Murdock said. “It put me at ease, and for someone with anxiety that’s a really big deal.”
Murdock is just one of the many people turning to the herbal drug for help.… Continue reading.READ MORE
On June 25, FDA issued warning letters to two marketers and distributors of kratom products – Cali Botanicals and Kratom NC. FDA determined that the companies were illegally selling unapproved, misbranded kratom-containing drug products with unproven claims about their ability to treat or cure opioid addiction and withdrawal symptoms. Additionally, FDA found that the companies also made claims about treating pain, as well as other medical conditions like depression, anxiety, and cancer.
In FDA’s press release, Acting FDA Commissioner Ned Sharpless noted that there are no FDA-approved uses for kratom and the agency has been active in warning consumers about the serious risks associated with kratom.… Continue reading.
The US Food and Drug Administration (FDA) earlier this month warned Chinese drugmaker Xi’an Livingbond Nonwoven Products Corp. and Indian homeopathic drugmaker Rxhomeo Private Limited over good manufacturing practice (GMP) violations stemming from inspections conducted earlier this year.
Based on the observations identified during the inspections, FDA placed the firms on Import Alert in April and May, respectively.
FDA also announced Tuesday that it has warned two US-based companies, Kratom NC and Cali Botanicals, for marketing kratom products through their websites and social media.
In its warning letter to Xi’an Livingbond, FDA cites the company for failing to conduct identity and strength testing for some of its products and for lacking both an adequate quality control unit and an effective program for monitoring manufacturing operations.… Continue reading.
“Two in 2017, one was where kratom was actually listed as the cause of death and the other one it was an incidental finding. We had the exact same numbers in 2018 where we had one kratom death where it was listed as the cause of death, the other, it was an incidental finding on the autopsy,” said Jefferson Parish coroner Gerry Cvitanovich.… Continue reading.READ MORE
Island News: If It Matters To You, It Matters To Us… Continue reading.READ MORE